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Summary
The liver is the only internal human organ capable of natural
regeneration of lost tissue, as little as 25%of a liver can regenerate
into a whole liver. The process of aging predisposes to hepatic
functional and structural impairment and metabolic risk. There-
fore, understanding how aging could affect the molecular pathol-
ogy of liver diseases is particularly important, and few studies to
date have tackled this complex process. The most common liver
disease, affecting one-third of the overall population, is nonalco-
holic fatty liver disease (NAFLD), characterized by an intrahepatic
accumulation of lipids. NAFLD can evolve into nonalcoholic
steatohepatitis (NASH) in the presence of oxidative stress and
inflammation.NASH is a serious risk factor fordisablinganddeadly
liver diseases such as cirrhosis and hepatocellular carcinoma (HCC).
Old age seems to favor NAFLD, NASH, and ultimately HCC, in
agreement with the inflamm-aging theory, according to which
aging accrues inflammation. However, the incidence of HCC drops
significantly in theveryelderly (individuals agedmore than70) and
the relationship between the progression of NAFLD/NASH/HCC
and very old age is obscure. In this review,wediscuss the literature
andweargue that theremight bean agewindow inwhich the liver
becomes resistant to the development of injury; this needs to be
studied to understand fully the interaction between age and liver
diseases from a therapeutic perspective.
Key words: aging; cytokines; demography; injury; insulin/
IGF-1 signalling; reactive oxygen species; mouse models;
NAFLD; NASH.
Aging and liver function
The aging of a vast majority of the population is a very recent
phenomenon that has emerged as a direct consequence of the rise in
human life expectancy (WHO, 2002). Longer life span, however, does
not necessarily mean a prolonged healthspan, as indicated by the
steep rise in the number of elderly individuals suffering from chronic
diseases, including metabolic and cardiovascular disease. Although
aging is not a disease, it is considered the leading risk factor for all
chronic diseases, accounting for 60% of all deaths worldwide (WHO,
2009). Aging refers to a multidimensional process of organism decline.
The liver is a vital organ with a wide range of functions, including
detoxification, protein synthesis, and production of compounds nec-
essary for digestion. Specific age-related hepatic changes have been
reported, such as increased hepatocyte size, increase in the number of
binucleated cells, and reduction in mitochondrial number (Premoli
et al., 2009; Gan et al., 2011). These changes may significantly affect
liver morphology, physiology, and oxidative capacity. Also, in the
elderly population, there is a one-third loss of hepatic volume and
perfusion between the ages of 30 and 100 years (Wynne et al., 1989),
a loss which has been reported to interfere with hepatic phase 1 drug
pharmacokinetics (Marchesini et al., 1988; Wynne et al., 1989;
Schmucker, 2005).
At the level of single-cell populations, a sharp decline in hepatic
regeneration following hepatectomy or chemical injury has been
observed during aging (Bucher et al., 1964; Stocker & Heine, 1971;
Popper, 1986; Jin et al., 2009a). Indeed, in young rats, all hepatocytes
enter the cell cycle after 70% liver resection, whereas only one-third do
so in the aged liver (Stocker & Heine, 1971). The molecular basis for the
loss of regenerative capacity of aged livers is just starting to be elucidated
and may involve CCAAT/enhancer-binding protein (C/EBP) family mem-
bers (a, b, c), GSK3b, HDAC1, and SIRT1 epigenetic and signaling
pathways (Gagliano et al., 2007; Jin et al., 2009a, 2011; Timchenko,
2009; Jiang et al., 2013). Interestingly, transgenic mice having under-
gone replacement of C/EBPalpha with C/EBPbeta, generating beta/beta
alleles, are long-lived (Chiu et al., 2004), and targeting GSK3b, HDAC1,
and SIRT1 enzymatic activities has been proposed to improve the course
of various age-related diseases (Lucas et al., 2001; Willis-Martinez et al.,
2010; Guarente, 2011).
Worth noting is that aging is associated with a physiological increase
in lipid accumulation in nonadipose tissues, including the liver (Petersen
et al., 2003; Slawik & Vidal-Puig, 2006). As with other organs,
accumulation of lipids in the liver may compromise their normal
functionality by promoting organ-specific toxic reactions, also known
as lipotoxicity (Slawik & Vidal-Puig, 2006). Aging markedly increases the
prevalence of the metabolic syndrome in the human population (Ford
et al., 2002). Accumulating evidence also points toward an increased
prevalence of nonalcoholic fatty liver disease (NAFLD) with older age in
humans (Floreani, 2007). NAFLD includes a wide spectrum of liver
pathologies ranging from benign hepatic lipid accumulation (steatosis) to
advanced nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and
ultimately hepatocellular cancer (HCC) (De Minicis et al., 2013). Aging
has also been reported to significantly enhance the progression to NASH
and fibrosis, thus predisposing to increased mortality in elderly subjects
with NAFLD (Regev & Schiff, 2001; Frith et al., 2009). However, is the
higher prevalence of NAFLD seen in the elderly population a result of
physiological changes intrinsic to the aging process or may it reflect age-
long compensation for lifestyle-associated factors, like obesity and
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nutritional oversupply? Is aging then an actual risk factor for liver
diseases, or a bystander? This review discusses the evidence both
supporting and confuting the interrelationship between aging and
NAFLD, NASH, and HCC. We will not cover here the role of superim-
posed challenges such as viral hepatitis or alcohol consumption during
aging.
Aging and nonalcoholic fatty liver disease (NAFLD)
NAFLD is the most common chronic liver pathology in the United States,
affecting almost 40 million obese adults or 15% of the population. It is
also the 4th most common reason for liver transplants. About 30.1
million obese adults contract liver steatosis and 8.6 million develop NASH
(Angulo, 2002). NAFLD is regarded as the hepatic manifestation of the
metabolic syndrome, a cluster of abnormalities that includes insulin
resistance and predisposes to type 2 diabetes and cardiovascular disease.
Insulin resistance, whether acquired or genetically determined, is found
in approximately 60% of all patients with NAFLD. Insulin resistance is
believed to be the primary cause of NAFLD. In a hyperinsulinemic state,
there is a failure to suppress the flux of free fatty acid derived from the
expanding adipose tissue mass, resulting in enhanced fat uptake by the
liver (Tilg & Moschen, 2008). In addition, insulin continues to activate
lipogenesis, thereby accelerating fatty acid synthesis and triglyceride
accumulation in the liver, further driving NAFLD (Brown & Goldstein,
2008). Although NAFLD is a strong and independent predictor for the
development of type 2 diabetes, the link between insulin resistance and
NAFLD has not always been demonstrated and there are a number of
studies reporting dissociation of NAFLD from insulin resistance in genetic
mouse models and in patients (Aparicio-Vergara et al., 2013; Sun &
Lazar, 2013).
NAFLD is a progressive disease characterized by hepatic fat
accumulation (liver steatosis) in the early stages and hepatic inflam-
mation driving the transition from benign steatosis toward more
advanced NASH (Fig. 1). While the disease is reversible in its early
stages, its treatment becomes more complicated in the advanced state.
If not treated, NASH may progress to cirrhosis, which is an irreversible
state of the disease characterized by scars on the liver tissue that can
possibly lead to HCC (Podrini et al., 2013) (Fig. 1). Although it is much
debated whether insulin resistance is a cause of age-associated
metabolic disturbances or rather a protective adaptive mechanism
(Barzilai & Ferrucci, 2012), it is generally believed that age is a risk
factor for increased hepatic steatosis. Fat may accumulate in the liver
as a result of multiple abnormalities of hepatic lipid metabolism,
although the mechanisms that underlie this age-related liver steatosis
are yet to be clearly defined. These mechanisms may include enhanced
fat uptake, increased de novo lipogenesis, decreased b-oxidation, and/
or decreased synthesis/secretion of very low-density lipoproteins
(Cohen et al., 2011). Consistent with this, b-oxidation has been
reported to decline in livers with old age, involving reduced hepatic
expression of nuclear receptor peroxisome proliferator-activated recep-
tor (Sanguino et al., 2004). Other studies have highlighted an
important role for augmented hepatic-adrenergic signaling in the
induction of liver steatosis with aging (Katz et al., 1993; Ghosh et al.,
2012), although the specific mechanisms underlying b-adrenergic-
mediated lipid accumulation with age remain undefined (Ghosh et al.,
2012). However, Jin et al. recently provided a clear molecular
mechanism for the age-associated development of steatosis by
demonstrating that p300-dependent regulation of chromatin structure
during aging causes the activation of 5 key genes that drive triglyceride
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Fig. 1 Schematic illustration of the pattern of liver disease progression during aging. The incidence of liver diseases in humans increases with age up to 75 years.
Interestingly, subjects aged more than 75 have a significantly reduced incidence of hepatocellular cancer (HCC) (left). The different states of liver disease progression (NAFLD,
nonalcoholic steatohepatitis (NASH), cirrhosis, and HCC) and the respective molecular changes are represented on the right. See text for details.
Liver diseases and aging, F. Sheedfar et al. 951
ª 2013 the Anatomical Society and John Wiley & Sons Ltd
BP-DGAT2 pathway is activated in human NAFLD, indicating that p300
and C/EBP proteins are essential participants in hepatic steatosis with
age in both mice and humans (Jin et al., 2013). In addition,
hypercholesterolemia (Bonomini et al., 2013), accumulation of reactive
oxygen species, DNA damage (Aravinthan et al., 2013), telomere
shortening (Tomas-Loba et al., 2013), decrease in autophagy (Amir &
Czaja, 2011), activation of nuclear factor-kappa B (NF-jB) signaling
(the master regulator of inflammatory responses) (Franceschi et al.,
2000), and metabolic dysfunction (Rodriguez et al., 2007) have also
been suggested as contributing factors. Detrimental factors that
synergistically exacerbate the clinical spectrum of NAFLD during aging
are cigarette smoking and a sedentary lifestyle (Breitling et al., 2009;
Booth et al., 2011). Remarkably, the above-mentioned physiological
decline in liver blood flow associated with aging is not affected by
smoking habits (Vestal & Wood, 1980). Recent data also demonstrate
a strong correlation between hepatocyte senescence markers and
NAFLD (Park et al., 2010; Aravinthan et al., 2013). Although aging has
been reported to increase lipid accumulation in the liver (Petersen
et al., 2003; Honma et al., 2011; Ghosh et al., 2012), Fontana et al.
recently showed a different view of the impact of aging on NAFLD
development (Fontana et al., 2013). By putting young (2 months old),
middle-aged (8 months old), and aged (18 months old) mice on a
high-fat regimen diet for 16 weeks, Fontana et al. demonstrated that
aging per se does not affect the development of simple steatosis
(Fontana et al., 2013). However, aging had an important role in
inducing liver damage, increased proinflammatory M1 macrophage
polarization and therefore increased inflammatory response and
development of NASH (Fontana et al., 2013). A recent clinical study
by Noureddin et al. enrolling 735 nonelderly (18–64 years old, average
47  11) and 61 elderly patients (>65 years old, average 68  3),
both groups displaying NAFLD, showed that elderly patients had a
higher prevalence of NASH and advanced fibrosis, as well as other
features of severe liver disease (Noureddin et al., 2013). Though, a
much larger population-based study to describe the prevalence of
NAFLD in the elderly (the Rotterdam study), enrolling 2811 individuals,
showed that NAFLD was found in 35.8% of participants aged
<70 years (n = 455), in 36.6% of participants aged 70–74 (n = 809)
years, in 39.6% of participants aged 75–79 years (n = 787), in 32.1%
of participants aged 80–84 years (n = 495), and in 21.1% of partic-
ipants aged older than 85 years (n = 265): overall, a clear trend of
decline in the incidence of NAFLD in the very elderly as age advances
(Koehler et al., 2012). Even if hepatic steatosis is considered intrinsic to
disease development, advanced liver fibrosis in NASH is often accom-
panied by a reduction in steatosis to the point of complete fat loss (van
der Poorten et al., 2012). This paradoxical but well-replicated finding is
known as burnt-out NASH and may be related to a number of
proposed mechanisms including elevations in serum adiponectin levels
(van der Poorten et al., 2012), portosystemic shunting (Nosadini et al.,
1984), changes in mitochondrial metabolism (Caldwell & Crespo,
2004), the inflammatory, catabolic state accompanying cirrhosis
(McCullough & Raguso, 1999), and collagen deposition in the liver
(Noureddin et al., 2013). Given that elderly patients have more severe
liver disease as compared with nonelderly patients (Koehler et al.,
2012; Noureddin et al., 2013), this resolution of hepatic steatosis may
in part explain the reduction in NAFLD prevalence with advanced age.
We propose that the discrepancy between the studies showing
increased NAFLD prevalence and severity and those showing an
attenuation is due to the fact that the former ones were conducted in
middle-aged/old, rather than in very old mice and humans (Vinciguerra,
2012; Fontana et al., 2013; Noureddin et al., 2013).
Aging liver, caloric restriction, and growth
hormones
Physical activity andnutritional habits are variables in lifestyle that decrease
the incidence of some age-related diseases (Pekkanen et al., 1987; Blair
et al., 1995),which have beenpositively associatedwith longevity. Also, in
the last 80 years, caloric restriction (CR) has been demonstrated to
increase the maximum life span in yeast, worms, flies, and rodents
(Partridge, 2012). As previous studies in centenarians have shown (Tietz
et al., 1992; Chan et al., 1999), overall liver function under normal
physiological conditions is not dramatically impaired with aging. Only
whenplaced under stressful conditions, such as hepatectomyor acute liver
injury, the liver may take a long time for regenerating. One of the features
of the agingprocess,whichdirectly or indirectly affects liver function, is the
gradual decline of growth hormone (GH) and insulin-like growth factor 1
(IGF1), which undergo a 50% reduction between the ages of 20 and 75
(Floreani, 2007) (Fig. 1). Components of the IGF1 pathway such as PI3K/
AKT and GSK3beta (Jin et al., 2009b) have been demonstrated to
control hepatocyte senescence by increasing the levels of cyclin D3 and by
holding them in a G1 phase through a mechanism mediated by C/EBPa.
Under normal conditions, the old liver is not able to regenerate properly
and, when stressed, will respond differently as compared to younger
tissue (Smith & Pereira-Smith, 1996; Gagliano et al., 2007). However,
uncontrolled activation of this regenerative process has been demon-
strated to be crucial for the development of HCC in a C/EBPa-dependent
manner (Wang et al., 2004). The natural decline of the PI3K/AKT and
GSK3 axis during aging can be seen as a positive feature whereby these
hormonal changes may drive the cell to enter a protective mode against
the development of HCC (Wang et al., 2004) (Fig. 1). The decrease of GH
obtained with CR extends life span in a variety of in vivo models and has
shown significant benefits in recovery from liver steatosis in humans
undergoing prolonged fasting or a diet based on 500 kcal day1
consumption for periods of 2.5 and 5 months, respectively (Harrison &
Day, 2007). The upregulation of GH/IGF1 in hepatocytes is thus an
example of antagonistic pleiotropy whereby cellular proliferation allows
for a better recovery from liver injury but may lead to HCC. In addition to
the modification of the IGF1/AKT axis and C/EBPa, aging also causes an
increase in the protein levels of histone deacetylase 1 (HDAC1) which, in a
liver-specific transgenic mousemodel, led to the development of steatosis
at a young age (Timchenko, 2009). An increased protein level of HDAC1 is
also involved in tumor development (Halkidou et al., 2004).
Inflamm-aging and liver function
As originally proposed by Franceschi (Franceschi et al., 2000), the aging
process is driven by an unbalanced stimulation/response of the immune
system, characterized by increased levels of inflammatory markers such as
cytokines, chemokine, reactive oxygen species (ROS), as well as decreased
levels of antioxidant enzymes such as superoxide dismutase (SOD) and
phase 1 detoxifying enzymes (inflamm-aging theory). According to this
theory, the persistence of inflammatory stimuli over time represents the
biological background favoring susceptibility to age-related diseases/
disabilities (Fig. 1). It is important to stress that the natural decrease in GH/
IGF-1 levels observed in elderly individuals is a feature that, although
beneficial, has to be coupled with practices aimed at reducing the
increased levels of inflammation in order to lead to healthy aging. Another
physiological change that negatively influences liver function is the
redistribution of adipose tissue from subcutaneous to visceral sites
(Tchkonia et al., 2010). In addition, in old age, fat is redistributed outside
fat depots resulting in ectopic lipid accumulation in nonadipose tissues
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including heart, skeletal muscle, and liver, even in lean individuals (Slawik
& Vidal-Puig, 2006; Tchkonia et al., 2010). This is associated with
increased mortality and risk of disorders such as hypertension, athero-
sclerosis, hyperlipidemia, insulin resistance, and diabetes, all of which
increase the chances of developing NAFLD (Tran et al., 2008). Counter-
acting inflamm-aging and adipose tissue redistribution in older people and
otherswith a lifestyle based on regular physical activity and reduced caloric
intake may be key factors for healthy aging.
Aging and hepatocellular carcinoma (HCC)
About 8–26% of individuals with NASH progress to cirrhosis, putting these
patients at a high risk of developing hepatocellular carcinoma (HCC)
(Podrini et al., 2013). HCC is among the top most common causes of
cancer-related mortality worldwide (Bosch et al., 2004). There are three
potentially curative modalities: percutaneous ablation, most commonly
called radiofrequency ablation, surgical resection, and transplantation. In
the majority of cases, HCC arises in the setting of cirrhosis, but hepatitis B
and C are the most common underlying etiologies (Nordenstedt et al.,
2010; Venook et al., 2010). However, HCC can also develop in a
background of ‘pure’ steatohepatitis (Rappa et al., 2013). HCC is very rare
before age 40 as it increases progressively with older age and peaks in
incidence around ages 70–75 (El-Serag, 2011). The aging liver in rodents
has been shown to provide a pro-proliferative environment (Pasciu et al.,
2006). Strong epidemiological data suggest that in humans the incidence of
HCC drops steadily and significantly in individuals older than 75, and up to
90+ (El-Serag, 2011, 2012) (Fig. 1). Concomitantly with the rising rates of
HCC, there is a shift of incidence from typically elderly patients to relatively
younger patients between ages 40 and 60 (El-Serag, 2011). This occurs
despite the fact that the number of elderly subjects diagnosed with HCC is
expected to increase in developed countries because of the rising incidence
of NASH-related liver disorders such as cirrhosis (Bugianesi, 2007). Are then
the very elderly protected against developing HCC? The mice studies
discussed above (Fontana et al., 2013) are in line with the inflamm-aging
theory, according to which aging accrues liver inflammation and induces
NASH, but show that aging per se does not affect steatosis. The oldestmice
group studied was fed a high-fat diet starting at an age of 18 months and
was analyzed 16 weeks later at 22 months (Fontana et al., 2013). Amouse
of 18 weeks corresponds roughly to a human aged 56, and a mouse of
22 months to a human aged 69 years (Flurkey et al., 2007), which is not
considered very elderly. As noted, NASH is a common precursor of HCC,
and there are only inconclusive data available on the progression ofNASH in
the very elderly (Gan et al., 2011). The relationship between very old age,
NASH, and HCC is complex and far from understood.
Conclusions
Due to the fact that every lifestyle embarked on by each of us is made
up of a number of variables affecting the aging process and having
different grades of severity, when discussing age-related diseases such
as NAFLD, NASH, and HCC, biological age, which reflects health status
rather than chronological age, should be carefully considered. The
epidemiological and laboratory data discussed here suggest that there
might exist an age window in which the livers of very elderly ‘survivors’
(mice or humans) become resistant to the development of injury. On
the other hand, it is possible that the observed lower prevalence of liver
diseases in old age may be the result of a survival bias, which is
not possible to determine in cross-sectional studies. We propose that
these phenomena need to be studied further to understand fully
the interaction between age and liver diseases from a therapeutic
perspective, and extending this understanding to other organs may
uncover a potential mechanism of longevity in a wider context.
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